Goldline Pharmaceutical H1 FY27 Net Profit Rises 44.5% YoY to Rs 205.15 Lakh
Goldline Pharmaceutical Ltd 路 Outcome 路 15 Nov 2026, 1:03 am
Goldline Pharmaceutical H1 FY27 Net Profit Rises 44.5% YoY to Rs 205.15 Lakh Goldline Pharmaceutical reported standalone revenue from operations of Rs 1,492.50 lakh for the half year ended 30th Sep'26, up 7.4% YoY from Rs 1,389.21 lakh in H1 FY26. Profit before tax rose 25.1% YoY to Rs 231.51 lakh compared to Rs 185.09 lakh. Net profit surged 44.5% YoY to Rs 205.15 lakh versus Rs 141.96 lakh, while basic and diluted EPS expanded to Rs 2.31 from Rs 1.96. Net cash flow from operating activities stood at Rs 10.93 lakh, with total cash and cash equivalents ending at Rs 155.52 lakh.
Original exchange filing (PDF)
More announcements from Goldline Pharmaceutical Ltd
- Submission of statement of deviation and variation of the half year ended 30th september 2026 路 15 Nov 2026
- Declaration of Un-audited Standalone Financial Results of the company for the half year ended September 30, 2026 路 15 Nov 2026
- Goldline Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve The Standalone Unaudited .... 路 14 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Laxmikant Mujumdar 路 01 Sept 2026
- Scrutinizer Report 路 31 Aug 2026
- AGM Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26. 路 30 Aug 2026
